Stay updated with breaking news from Array Biopharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4 billion acquisition of Array Biopharma in 2019.
Lackluster initial results forces Pfizer to discontinue Phase III trial on a potential drug for symptomatic dilated cardiomyopathy (DCM).
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors - read this article along with other careers information, tips and advice on BioSpace
Anixa Biosciences (NASDAQ:ANIX – Get Rating) and ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Earnings and Valuation This table compares Anixa Biosciences and […]
First study conducted in the adjuvant setting with a combination of BRAF and MEK inhibitors in high-risk stage II BRAF V600E/K-mutant cutaneous melanomaA global partnership between EORTC and